The FDA agreed that the design of a Phase 3 trial testing privosegtor in optic neuritis could support a future approval application.

WHO says the initiative is part of a broader effort to strengthen global research systems, improve public trust in science, ...

In a recent video interview with Applied Clinical Trials, Sam Hinsley, statistics manager at Phastar, discussed the critical ...

Clinical trials are notoriously expensive, time consuming, and risky. Failure comes at a very high cost (millions of dollars and months of development time wasted), yet studies show that the rate of ...

In this video interview, Sam Hinsley, statistics manager at Phastar, reflects on why she chose a career in clinical trials ...

If researchers hope to lean on data from a single trial for therapeutic approval, it is important to communicate with the FDA ...

Despite being a cornerstone of cancer treatment advancement, clinical trials remain inaccessible for many patients because of structural, socioeconomic, and systemic barriers. In this ...

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and ...

The integration of real-world data (RWD) into protocol feasibility and site selection has emerged as a clinical trial game-changer in recent years. Traditionally relying heavily on data from carefully ...

Furthermore, increasing complexity in cancer clinical trial design has led to challenges such as protocol deviations, slow enrollment leading to lengthened durations of trial, and escalating costs. By ...